Sevasemten 10 mg
EDG-5506-201
Phase 2 small_molecule active
Quick answer
Sevasemten 10 mg for Becker Muscular Dystrophy is a Phase 2 program (small_molecule) at Edgewise Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Edgewise Therapeutics
- Indication
- Becker Muscular Dystrophy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active